

RESEARCH REPORT

Orthocell Limited (ASX: **OCC**) (Company) advises that Argonaut has published a research note on the Company.

A copy of the report can be found under the Investors - Analyst Coverage menu of the Company's website below.

<http://orthocell.com.au>

Disclaimer

This information is produced by a third party (Third Party Information). Orthocell Limited (Company) did not commission Argonaut to conduct this report. It may contain information about the activities of Orthocell Limited but it does not purport to be a complete description of the Company and/or its various business activities. No representation or warranty, express or implied, is made by any person including Orthocell Limited or its directors, officers, employees, advisers, agents or affiliates as to the fairness, accuracy, completeness, or correctness of the information, opinions and conclusions contained in this Third Party Information, or as to the reasonableness of any assumptions, forecasts, prospects or returns contained in, or implied by, this Third Party Information or any part of it. Orthocell Limited assumes no liability and has no obligation to tell recipients if it becomes aware of any inaccuracies in or omissions from Third Party Information.

Except for statutory liability which may not be excluded, no responsibility is accepted by Orthocell Limited or any of its directors, officers, employees, advisers, agents or affiliates for any loss or damage howsoever occurring (including through negligence) resulting from the access, use or reliance upon any Third Party Information by any person, and any such access, use or reliance is solely at your own risk. You are responsible for forming your own opinions and should seek your own independent professional advice in relation to Third Party Information. In particular, you are cautioned not to place undue reliance on any forward-looking statements, forecasts or views as to prospects in any Third Party Information, as there can be no assurances that actual outcomes will not differ materially from such forward-looking statements.

ENDS





For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited, Managing Director

P: (08) 9360 2888
E: paulanderson@orthocell.com.au

Media enquiries

Gavin Lower
Buchan Consulting

P: (03) 8866 1215
M: 0414 796 726
E: glower@buchanwe.com.au

Investor Relations

Ben Walsh
Buchan Consulting

P: + 61 468 422 865
E: bwalsh@buchanwe.com.au

About Orthocell Limited

Orthocell is a commercial-stage, regenerative medicine company focused on regenerating mobility for patients and our ageing population by developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell's portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is CelGro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au

